These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38289962)

  • 1. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.
    Yu Z; Deng P; Chen Y; Lin D; Liu S; Hong J; Guan P; Chen J; Zhong ME; Chen J; Chen X; Sun Y; Wang Y; Wang P; Cai Z; Chan JY; Huang Y; Xiao R; Guo Y; Zeng X; Wang W; Zou Y; Yu Q; Lan P; Teh BT; Wu X; Tan J
    Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2304619121. PubMed ID: 38289962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Flatmark K; Saelen MG; Hole KH; Abrahamsen TW; Fleten KG; Hektoen HH; Redalen KR; Seierstad T; Dueland S; Ree AH
    Radiother Oncol; 2016 Jun; 119(3):505-11. PubMed ID: 26968754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
    Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
    BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
    Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Matsuzaki H; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Yamamoto Y; Oba K; Ishihara S
    BMC Cancer; 2023 May; 23(1):450. PubMed ID: 37198556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
    Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.
    Li ZY; Wang XD; Li M; Liu XJ; Ye Z; Song B; Yuan F; Yuan Y; Xia CC; Zhang X; Li Q
    World J Gastroenterol; 2020 May; 26(19):2388-2402. PubMed ID: 32476800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
    Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
    Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
    Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes.
    De Felice F; Llange K; Rubini F; Bulzonetti N; Caiazzo R; Musio D; Tombolini V
    Clin Colorectal Cancer; 2018 Mar; 17(1):e77-e81. PubMed ID: 29113729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
    Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
    Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
    BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.
    Fu XL; Fang Z; Shu LH; Tao GQ; Wang JQ; Rui ZL; Zhang YJ; Tian ZQ
    Oncotarget; 2017 May; 8(21):34340-34351. PubMed ID: 28423720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
    BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.
    Dueland S; Ree AH; Grøholt KK; Saelen MG; Folkvord S; Hole KH; Seierstad T; Larsen SG; Giercksky KE; Wiig JN; Boye K; Flatmark K
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):532-9. PubMed ID: 26888115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.